NAMS (NewAmsterdam Pharma Co NV) Float Percentage Of Total Shares Outstanding: 85.47% (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
45 GF Score
Price $27.96
GF Value $10.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV Float Percentage Of Total Shares Outstanding?

NewAmsterdam Pharma Co NV NAMS +1.05% 45 Float Percentage Of Total Shares Outstanding is 85.47% as of Aug. 08, 2026. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NewAmsterdam Pharma Co NV's float shares is 102.17 Mil. NewAmsterdam Pharma Co NV's total shares outstanding is 119.54 Mil. NewAmsterdam Pharma Co NV's float percentage of total shares outstanding is 85.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NewAmsterdam Pharma Co NV's Insider Ownership is 0.46%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NewAmsterdam Pharma Co NV's Institutional Ownership is 106.25%.

NAMS
45GF Score
NewAmsterdam Pharma Co NV NAMS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewAmsterdam Pharma Co NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

NewAmsterdam Pharma Co NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=102.17/119.54
=85.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 85.47% mean?
NewAmsterdam Pharma Co NV (NAMS) has a Float Percentage Of Total Shares Outstanding of 85.47% as of Aug. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on NewAmsterdam Pharma Co NV and its competitors.
Is NewAmsterdam Pharma Co NV's Float Percentage Of Total Shares Outstanding too high?
NewAmsterdam Pharma Co NV's current Float Percentage Of Total Shares Outstanding is 85.47%. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Float Percentage Of Total Shares Outstanding compare to ARQT and IDYA?
NewAmsterdam Pharma Co NV's Float Percentage Of Total Shares Outstanding of 85.47% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current Float Percentage Of Total Shares Outstanding is 85.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 85.47%. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Float Percentage Of Total Shares Outstanding is 85.47% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • Float Percentage Of Total Shares Outstanding: 85.47%
  • GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score

Get the complete analysis for NAMS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.96
Price
$10.42
GF Value